CTLA4 and neoplasm: Mice that received [177Lu]Lu-DOTA-folate and anti-CTLA-4 immunotherapy (group D), responded in 8 out of 11 cases, demonstrated by decreasing tumor volumes over time, and in 7 cases the NF9006 tumors disappeared entirely (Fig. 4d).